AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by analysts at Kepler Capital Markets in a note issued to investors on Thursday.

Several other brokerages also recently weighed in on AZN. JPMorgan Chase & Co. set a GBX 6,500 ($84.93) price target on shares of AstraZeneca and gave the company a “buy” rating in a report on Tuesday, September 18th. Jefferies Financial Group reaffirmed a “hold” rating and set a GBX 5,800 ($75.79) price target on shares of AstraZeneca in a report on Friday, October 12th. Deutsche Bank reaffirmed a “buy” rating and set a GBX 6,500 ($84.93) price target on shares of AstraZeneca in a report on Monday, November 12th. Shore Capital reaffirmed a “hold” rating on shares of AstraZeneca in a report on Monday, October 22nd. Finally, Barclays reaffirmed a “top pick” rating and set a GBX 6,800 ($88.85) price target on shares of AstraZeneca in a report on Friday, November 9th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company’s stock. AstraZeneca has an average rating of “Hold” and an average target price of GBX 5,927.44 ($77.45).

Shares of LON:AZN opened at GBX 6,200 ($81.01) on Thursday. AstraZeneca has a 1-year low of GBX 4,260 ($55.66) and a 1-year high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: What is the quiet period?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.